LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Stock List・Ovid therapeutics Inc

Ovid therapeutics Inc

Closed

SectorHealthcare

2.79 1.45

Buy Sell

Overview

Share price change

24h

Current

Min

2.75

Max

2.79

Key metrics
By Trading Economics
Income	22M 9.7M
Sales	586K 718K
Profit margin	1,345.822
Employees	23
EBITDA	-152K -12M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+79.64% upside

Dividends
By Dow Jones
Next Earnings	12 May 2026

Market Stats
By TradingEconomics
Market Cap	368M 507M
Previous open	1.34
Previous close	2.79

News Sentiment

By Acuity

50%

159 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.275 / 0.33 Support & Resistance

Ovid therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 May 2026, 06:05 UTC

Earnings

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 May 2026, 23:55 UTC

Earnings

Review & Preview: Still Going Strong -- Barrons.com

8 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 20:49 UTC

Earnings

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 May 2026, 20:25 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Net $115M

8 May 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 May 2026, 19:18 UTC

Earnings

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 May 2026, 19:16 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:08 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:05 UTC

Earnings

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 May 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 May 2026, 18:51 UTC

Earnings

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 May 2026, 18:49 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 18:41 UTC

Earnings

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 May 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 May 2026, 17:14 UTC

Earnings

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 May 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 May 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 May 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 May 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 May 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 May 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8 May 2026, 15:20 UTC

Market Talk

Earnings

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 May 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 May 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

Peer Comparison

Price change

Ovid therapeutics Inc Forecast

Price Target

By TipRanks

79.64% upside

12 Months Forecast

Average 5.03 USD 79.64%

High 7 USD

Low 4 USD

Based on 8 Wall Street analysts offering 12 month price targets forOvid therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Ovid therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.275 / 0.33Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

159 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.